Lupin Limited has informed the Exchange about Lupin Healthcare (UK) Limited, a wholly owned subsidiary of the Company having acquired the entire share capital of Renascience Pharma Limited, United Kingdom.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin Limited announced that its wholly owned UK subsidiary, Lupin Healthcare (UK) Limited, has acquired the entire share capital of Renascience Pharma Limited, based in the United Kingdom. The deal was completed through the subsidiary route, meaning Lupin now has full ownership of the UK-based Renascience Pharma. No financial details such as deal value, revenue contribution, or strategic rationale have been disclosed in this filing. This expands Lupin's UK and European footprint through inorganic growth.
This is a subsidiary-level acquisition that strengthens Lupin's UK presence, but the lack of disclosed deal value or business details limits immediate assessment. Shareholders should watch for further disclosures on deal size, Renascience's product portfolio, and revenue contribution to gauge the strategic value.